Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

74.16 +0.48 (+0.65%)
Streaming Delayed Price Updated: 11:27 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity. 
Via Chartmill
News headline image
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage... 
Via MarketMinute
Topics Death
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
PTC Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗
PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗
PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗
PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗
PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech. 
Via Chartmill
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
News headline image
Here's Why Shares in PTC Therapeutics Soared This Week ↗
An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful. 
Via The Motley Fool
News headline image
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump ↗
PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid. 
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock ↗
Discover PTC Therapeutics (PTCT), an affordable growth stock with strong revenue & EPS growth, low P/E ratio, and solid profit margins in the biotech sector. 
Via Chartmill
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided ↗
Via Stocktwits
News headline image
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns ↗
FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another controlled trial. 
Via Benzinga
News headline image
PTCT Earnings Beat but Sales Drop 4% ↗
Via The Motley Fool
Topics Earnings
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch ↗
PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a... 
Via Chartmill
Topics Earnings
News headline image
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics ↗
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact. 
Via Benzinga
News headline image
These Analysts Increase Their Forecasts On PTC Therapeutics ↗
 
Via Benzinga
News headline image
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened ↗
The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation ↗
PTC Therapeutics (PTCT) offers strong growth potential with solid financials and attractive valuation, making it a top pick for investors seeking affordable growth in biopharma. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS INC (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, supported by solid financial health and profitability metrics. A biotech stock worth watching. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential ↗
PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.